Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00134-020-06153-9 http://scihub22266oqcxt.onion/10.1007/s00134-020-06153-9 32533197!7290076!32533197     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intensive+Care+Med 2020 ; 46 (7): 1339-1348 Nephropedia Template TP {{tp|p=32533197|t=2020. Acute kidney injury in critically ill patients with COVID-19 |pdf=|usr=}}{{32533197}} gab.com Text Acute kidney injury in critically ill patients with COVID-19 JO: Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=32533197 #FOAvip Acute kidney injury (AKI) has been reported in up to 25% of critically-ill patients with SARS-CoV-2 infection, especially in those with underlying comorbidities. AKI is associated with high mortality rates in this setting, especially when renal replacement therapy is required. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus. The pathophysiology of COVID-19 associated AKI could be related to unspecific mechanisms but also to COVID-specific mechanisms such as direct cellular injury resulting from viral entry through the receptor (ACE2) which is highly expressed in the kidney, an imbalanced renin-angotensin-aldosteron system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. Non-specific mechanisms include haemodynamic alterations, right heart failure, high levels of PEEP in patients requiring mechanical ventilation, hypovolemia, administration of nephrotoxic drugs and nosocomial sepsis. To date, there is no specific treatment for COVID-19 induced AKI. A number of investigational agents are being explored for antiviral/immunomodulatory treatment of COVID-19 and their impact on AKI is still unknown. Indications, timing and modalities of renal replacement therapy currently rely on non-specific data focusing on patients with sepsis. Further studies focusing on AKI in COVID-19 patients are urgently warranted in order to predict the risk of AKI, to identify the exact mechanisms of renal injury and to suggest targeted interventions. Twit Text FOAVip Acute kidney injury in critically ill patients with COVID-19 ????Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=32533197 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32533197 #FOAvip English Wikipedia <ref>{{Cite pmid|32533197}}</ref> Acute kidney injury in critically ill patients with COVID-19 #MMPMID32533197 Gabarre P; Dumas G; Dupont T; Darmon M; Azoulay E; Zafrani L Intensive Care Med 2020[Jul]; 46 (7): 1339-1348 PMID32533197show ga Acute kidney injury (AKI) has been reported in up to 25% of critically-ill patients with SARS-CoV-2 infection, especially in those with underlying comorbidities. AKI is associated with high mortality rates in this setting, especially when renal replacement therapy is required. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus. The pathophysiology of COVID-19 associated AKI could be related to unspecific mechanisms but also to COVID-specific mechanisms such as direct cellular injury resulting from viral entry through the receptor (ACE2) which is highly expressed in the kidney, an imbalanced renin-angotensin-aldosteron system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. Non-specific mechanisms include haemodynamic alterations, right heart failure, high levels of PEEP in patients requiring mechanical ventilation, hypovolemia, administration of nephrotoxic drugs and nosocomial sepsis. To date, there is no specific treatment for COVID-19 induced AKI. A number of investigational agents are being explored for antiviral/immunomodulatory treatment of COVID-19 and their impact on AKI is still unknown. Indications, timing and modalities of renal replacement therapy currently rely on non-specific data focusing on patients with sepsis. Further studies focusing on AKI in COVID-19 patients are urgently warranted in order to predict the risk of AKI, to identify the exact mechanisms of renal injury and to suggest targeted interventions. |Acute Kidney Injury/drug therapy/physiopathology/therapy/*virology[MESH] |Betacoronavirus/*isolation & purification/physiology[MESH] |Blood Coagulation Disorders/virology[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/metabolism/urine[MESH] |Creatinine/blood[MESH] |Critical Illness[MESH] |Hematuria/etiology[MESH] |Humans[MESH] |Kidney/physiopathology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/metabolism/urine[MESH] |Proteinuria/etiology[MESH] |Renin-Angiotensin System/*physiology[MESH] |SARS-CoV-2[MESH] |Urinalysis[MESH]Acute kidney injury in critically ill patients with COVID-19 (epmc).pdf DeepDyve Pubget Overpricing